Literature DB >> 1575182

Effect of spinal cord stimulation on regional myocardial perfusion assessed by positron emission tomography.

C De Landsheere1, C Mannheimer, A Habets, M Guillaume, I Bourgeois, L E Augustinsson, T Eliasson, D Lamotte, H Kulbertus, P Rigo.   

Abstract

Spinal cord stimulation (SCS) can relieve symptoms in patients with severe angina pectoris refractory to conventional medical or surgical therapy. This symptomatic improvement may result from decreased myocardial ischemia. To test this hypothesis, positron emission tomography (PET) and potassium-38 as a flow tracer were used in 8 patients for the quantitative evaluation of regional myocardial perfusion at rest and after exercise, before and during SCS. Potassium uptake was evaluated as myocardial clearance (flow times net extraction) in ml/min/100 g. Tomographic segments were categorized as nonaffected and affected on the basis of the absence or presence of arterial stenosis on coronary angiography and on the basis of thallium scintigraphic data. In nonaffected segments, before SCS, regional myocardial clearance significantly increased from rest (28 +/- 4) to exercise (47 +/- 13 clearance units; p less than 0.004). A similar increase occurred after SCS. In affected segments, before SCS, regional myocardial clearance barely increased (p = 0.065) from rest (26 +/- 6) to exercise (33 less than or equal to 12). In comparison, after SCS, the resting regional myocardial clearance was slightly elevated (29 +/- 8) reflecting an increased double product, but did not increase (p = 0.192) with exercise (34 +/- 12). However, the magnitude and duration of ST-segment depression decreased during treatment with SCS. Anginal pain occurred in all patients during control exercise, but was attenuated in all but one with SCS. These results indicate that SCS improves exercise-induced angina and electrocardiographic signs of ischemia but this influence does not appear to be mediated by changes in regional myocardial perfusion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575182     DOI: 10.1016/0002-9149(92)90926-p

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Neurostimulation treatment for angina pectoris.

Authors:  S Murray; P D Collins; M A James
Journal:  Heart       Date:  2000-02       Impact factor: 5.994

Review 2.  [Examination of myocardial perfusion with positron emission tomography: a clinically useful and valid method?].

Authors:  J vom Dahl
Journal:  Herz       Date:  1997-02       Impact factor: 1.443

3.  Spinal cord stimulation and coronary ischaemia.

Authors:  A Chauhan; M C Petch; P M Schofield
Journal:  BMJ       Date:  1993-10-09

Review 4.  Visceral chest pain in unstable angina pectoris and effects of transcutaneous electrical nerve stimulation. (TENS). A review.

Authors:  M Börjesson
Journal:  Herz       Date:  1999-04       Impact factor: 1.443

5.  Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris. The Working Group on Neurocardiology.

Authors:  I A TenVaarwerk; G A Jessurun; M J DeJongste; C Andersen; C Mannheimer; T Eliasson; W Tadema; M J Staal
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

6.  Esophageal visceral pain sensitivity: effects of TENS and correlation with manometric findings.

Authors:  M Börjesson; M Pilhall; T Eliasson; H Norssell; C Mannheimer; P Rolny
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

7.  Spinal Cord Stimulation for the Treatment of Angina Pectoris.

Authors:  Wilbert S. Aronow; William H. Frishman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-02

8.  A study to assess changes in myocardial perfusion after treatment with spinal cord stimulation and percutaneous myocardial laser revascularisation; data from a randomised trial.

Authors:  Sadia N Khan; Duncan C McNab; Linda D Sharples; Carol J Freeman; Ian Hardy; David L Stone; Peter M Schofield
Journal:  Trials       Date:  2008-02-28       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.